Drugs /

abbv-368

Back to Drugs List

Overview

Trade Name(s):
Revdofilimab
NCI Definition [1]:
An agonistic humanized IgG1 monoclonal antibody that recognizes the co-stimulatory receptor OX40 (CD134; tumor necrosis factor receptor superfamily member 4; TNFRSF4), with potential immunostimulatory activity. Upon administration, revdofilimab selectively binds to and activates OX40. This may induce the proliferation of memory and effector T-lymphocytes and inhibit the function of T-regulatory cells (Tregs) in the tumor microenvironment (TME). OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and plays an essential role in T-cell activation and differentiation.

Clinical Trials

View Clinical Trials for abbv-368

Abbv-368 has been investigated in 4 clinical trials, of which 3 are open and 1 is closed. Of the trials investigating abbv-368, 4 are phase 1 (3 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for abbv-368 clinical trials.

Hypopharyngeal squamous cell carcinoma, laryngeal squamous cell carcinoma, and malignant solid tumor are the most common diseases being investigated in abbv-368 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Abbv-368
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Abbv-368
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating abbv-368 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
revdofilimab, anti-ox40 agonistic monoclonal antibody abbv-368, agonistic anti-ox40 monoclonal antibody abbv-368, abbv368, abbv 368, anti-ox40 agonist monoclonal antibody abbv-368
Drug Target(s) [2]:
TNFRSF4
NCIT ID [1]:
C161864

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.